FAPi PET/CT scan for pancreatic ductal adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational imaging protocol using Ga-68 FAPi PET/CT to visualize fibroblast activation protein (FAP) in and around pancreatic ductal adenocarcinoma. The tracer (a Gallium-68–labeled FAP inhibitor peptide) binds to FAP expressed in the tumor microenvironment and PET/CT images are acquired to map tracer uptake. Patients enrolled are adults with biopsy-proven pancreatic adenocarcinoma and without concurrent malignancy, and pregnant or lactating patients are excluded. Images will be compared to standard imaging to characterize additional tissue detection beyond conventional CT.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any gender with age more than 18 years
* Patients with biopsy-proven pancreatic ductal adenocarcinoma
* Patient willing to participate in study

Exclusion Criteria:

* Patient with concurrent malignancy
* Pregnancy and lactation

Where it's running

• Tata Memorial Hospital, Mumbai, India
  Mumbai, Maharashtra, India Recruiting

Study contacts

• Principal investigator: Ameya Puranik, DNB — Tata Memorial Hospital, Mumbai
• Study coordinator: Sushil Yadav, MSc
• Email: sushilyadav.crc@gmail.com
• Phone: 912224177000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)

  This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.

  Recruiting Phase 1 Matter Bio, Inc. · The Bronx, New York · NCT07828236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.